Val replied the topic: Severely Under Valued Stocks
From the annual report 2016 of Star Pharmaceutical::
"We will also continue to develop new products through our R&D efforts to meet changing market needs. Currently, there are 14 on-going R&D projects in progress. Therefore, we expect our continuous investments in R&D to bear fruit soon
. With a strong product pipeline, coupled with aggressive business development initiatives to expand domestic sales and capture growth opportunities internally and externally, we are optimistic of delivering a better performance
in the future."